Stay updated on Pembrolizumab in HCC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in HCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in HCC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the number of subjects to be enrolled in the single-arm trial of pembrolizumab for advanced hepatocellular carcinoma after sorafenib failure. The change reflects an increase in the total number of subjects to be evaluated for the efficacy and safety of pembrolizumab in this medical study.
    Difference
    0.1%
    Check dated 2024-06-06T14:33:59.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study, specifying the requirements for inclusion and exclusion of participants. Previously, this section had no information provided.
    Difference
    29%
    Check dated 2024-05-22T21:11:29.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:47:37.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in HCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in HCC Clinical Trial page.